T(8;21) patients with AML with high serum Gal-3 levels may have unfavorable outcomes because of high CD56 expression in AML cells [46], which has been associated with extramedullary relapse [202,206]. This evidence concerns the gene NCAM1 and acute myeloid leukemia.